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Abstract
 Purpose—Causal effects in epidemiology are almost invariably studied by considering disease 
incidence even when prevalence data are used to estimate the causal effect. For example, if certain 
conditions are met, a prevalence odds ratio can provide a valid estimate of an incidence rate ratio. 
Our purpose and main result are conditions that assure causal effects on prevalence can be 
estimated in cross-sectional studies, even when the prevalence odds ratio does not estimate 
incidence.
 Methods—Using a general causal effect definition in a multivariate counterfactual framework, 
we define causal contrasts that compare prevalences among survivors from a target population had 
all been exposed at baseline with that prevalence had all been unexposed. Although prevalence is a 
measure reflecting a moment in time, we consider the time sequence to study causal effects.
 Results—Effects defined using a contrast of counterfactual prevalences can be estimated in an 
experiment and, with conditions provided, in cross-sectional studies. Proper interpretation of the 
effect includes recognition that the target is the baseline population, defined at the age or time of 
exposure.
 Conclusions—Prevalences are widely reported, readily available measures for assessing 
disabilities and disease burden. Effects on prevalence are estimable in cross-sectional studies but 
only if appropriate conditions hold.
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 Introduction
A now-common way to define causal effects in epidemiology uses a counterfactual 
framework [1–5]. Expanding on this approach, Flanders and Klein [6] presented a general 
definition of causal effects as a contrast of parameters of the distribution of multivariate 
counterfactual outcomes for the same population under two exposure conditions.
This general approach shows that causal effects can be defined using contrasts of 
prevalences [6,7]. Nevertheless, prevalences are infrequently used to define or estimate 
effects. For example in cross-sectional studies, prevalence odds ratios are often not viewed 
as causal measures unless they are a proxy for an incidence rate ratio [8–10]. Grabovschi et 
al. [11] seemingly echo this view, stating “The reviewed research studies also have some 
important methodological limitations related mostly to their reliance on survey data, which 
could preclude causal interpretation and only measure statistical associations and 
tendencies.”
Although some have defined [6] and others estimated [7] causal effects using prevalence 
contrasts, the conditions needed for valid estimation in cross-sectional studies have not yet 
been discussed. Therefore, our purpose here is to discuss valid estimation of causal effects 
when interest includes disease prevalence itself rather than just disease occurrence. We 
review the definition of a causal prevalence difference, provide examples, and discuss 
interpretation. Our main, new, and novel results are the presentation and discussion of 
assumptions that, when true, assure that causal effects on prevalence can be validly 
estimated in cross-sectional studies.
 Notation and definitions
We assume exposure (E) is dichotomous and occurs at an early age ao, if at all. Disease (D) 
can occur at any age, can resolve, in which case we say D is not present, and can recur in 
people in whom it had resolved.
 Notation
The outcome-vector [Di,a, Si,a] encodes disease status and survival: disease component Di,a 
is 1 if individual i is alive with disease and 0 otherwise and survival component Si,a is 1 if 
individual i is alive and 0 otherwise, both at age a. Ei is 1 if individual i was exposed at age 
ao and 0 otherwise. Parentheses denote counterfactual outcomes [1,12]: the vector [Di,a(e), 
Si,a(e)] is the value of [Di,a, Si,a] if Ei had been set to e at age ao, for e = 0,1. In particular, 
disease component Di,a(e) is 0 if individual i would have died before age a after setting Ei to 
e, but other definitions are possible [6,13,14].
Because an individual cannot have been both exposed and unexposed at age ao, one of the 
outcome vectors [Di,a(1), Si,a(1)] or [Di,a(0), Si,a(0)] is counterfactual.
 Definitions
Clear effect definitions require several components [2,6,15–17], including specification of 
the target; relevant ages including those when exposure is to be set and the outcome 
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measured (e.g., follow-up periods); how the exposure will be set to the levels considered; 
and the contrast (e.g., difference or ratio).
Assuming these components are specified, the effect of E on presence of D at age a for 
individual i can be defined as Di,a(1) − Di,a(0), Table 1. Because D encodes being alive with 
disease at age a, this effect is on the joint (composite) outcome having disease and being 
alive. Possible values are −1, 0, and +1. For example, −1 corresponds to being alive with 
disease presence D at age a if unexposed and either not having disease or not being alive if 
exposed. This definition differs from the typical one wherein those dying without disease are 
treated as incomplete observations; however, it is akin to the approach of Fine and Grey [18] 
wherein those dying without disease are treated as nondiseased, complete observations. 
Disease could potentially have changed several times between exposure at age ao and age a; 
focusing on age a summarizes net changes. The effect of exposure can depend on disease 
status at age ao.
To define a population average effect of E on disease presence at age a, we must specify the 
target population (P0) at age a0 when exposure is set. Then, we define the causal prevalence 
difference (cPD) at age a for P0 as the prevalence in P0 if all had been exposed at age a0, 
compared with that prevalence if all had been unexposed. In equation form, cPD is
(1)
The vectors [∑i∈P0 Di,a (e), ∑i∈P0 Si,a (e), e = 0, 1] whose components appear in Equation 1 
are parameters (means) of the distributions of counterfactual outcome vectors. If exposure 
affects survival, that would be part of the causal pathway and reflected in cPD. Importantly, 
the target is P0, not the subpopulation that survives to age a.
Of note, Flanders and Klein [6] previously defined causal effects using prevalence ratios 
rather than differences. Then, the target population was Pf, the full population at baseline. 
Now the target population (P0) coincides with Pf, provided the survey population P1 consists 
of all survivors from Pf. Thus, apart from changing from ratios to differences, the previous 
[6] and present definitions essentially coincide.
 Estimation
A natural estimator of the population average causal effect of E on presence of D in 
population P0 is the observed difference:
(2)
where an overbar indicates the average; D̅j,a1 = ∑i∈P0: Ei = jDi,a1/Nj,a1 = ∑i∈P0:Ei=jDi,a1/
∑i∈P0:Ei=jSi,a1 is the observed prevalence of D at age a = a1 in exposure group j (j = 1 if 
exposed, 0 otherwise); and Nj,a1 is the observed number alive with exposure equal to j at age 
a1.
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In results, we present assumptions that suffice for this estimator to be unbiased in cross-
sectional studies; in Appendix 1, we justify this claim, and in Appendix 2, we discuss why 
the estimator is unaffected by collider bias from conditioning on survival.
Of note, this estimator is simple and involves directly observable variables. As in the 
definition, deaths including those from “competing risks” are treated realistically, as part of 
the causal process affecting disease prevalence.
 Results
Our goal and main novel result is to state assumptions sufficient for expression [2] to be a 
valid estimator of causal prevalence differences in cross-sectional surveys. We first motivate 
the approach by briefly considering experiments.
 Randomized experiments
The effects of exposure on disease presence at a specified time after exposure can be 
estimated in an experiment. Briefly, one identifies and enrolls subjects, say at age a0. For 
simplicity, we focus throughout on a specific age at exposure (a0), although one could 
include different age groups and calculate a summary measure or model age patterns. We 
may optionally measure baseline presence of disease (age a0) and then expose a random 
subgroup to E or placebo. We follow the cohort to age a1 and measure disease presence, 
assuming no dropouts or loss to follow-up.
Sufficient conditions under which estimator 2 validly estimates causal effects in randomized 
experiments are exchangeability (Table 1) for disease presence and survival [Di,a(e), Si,a(e)]; 
independence between people (stable unit treatment value assumption, SUTVA [19,20]); and 
counterfactual model consistency [4] (Table 1; e.g., Di,a(j) = Di,a, if Ei = j). The target is the 
baseline cohort, and all subjects remain under observation, unless death intervenes. These 
assumptions describe good randomization (exchangeability), no intersubject interference 
(SUTVA), complete follow-up, and conceptual clarity (consistency), respectively. They 
should hold in a well-conducted experiment, possibly apart from SUTVA which can depend 
on characteristics of the exposure and outcome. Example 1 illustrates how causal effects 
might be estimated using prevalence contrasts. Additional examples are provided by 
community intervention trials, often randomized, that frequently use prevalence contrasts to 
estimate causal effects [21]. Cohort studies involve similar assumptions, with the important 
caveat that, absent randomization, exchangeability is not necessarily expected (see Appendix 
1).
Exchangeability need hold only conditional on measured baseline covariates (C; Table 1). 
Moreover, the target need not be disease free (at baseline). However, the assumption of 
exchangeability for nonrandomized studies could be implausible if the prevalence at baseline 
differed by exposure as noted in the discussion.
 Example 1
We illustrate estimation of effects on prevalence in an experiment. Kuller et al. [22] studied 
the effect of a healthy lifestyle intervention on women’s low-density lipoprotein (LDL) 
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cholesterol. Women had similar cholesterol levels at baseline, but 4.5 years after 
randomization, 27% of the women in the lifestyle intervention group had LDL cholesterol 
<100 mg/dL (“optimal”) compared with 16% in the assessment only group. Many measures 
and comparisons were additionally reported (e.g., average between-group differences), but 
results included these prevalences illustrating that prevalences can be relevant and 
informative.
From their results, the prevalence difference is 27% − 16% = 9%. This contrast is not only 
descriptive, but with our assumptions that should often be plausible in a randomized 
experiment (previously mentioned), can also be interpreted as estimating the causal effect of 
the intervention on prevalence of optimal LDL cholesterol. Because prevalence reflects both 
incidence and duration after onset [23], effect can be on both—as summarized in the 
prevalence difference. Follow-up was high (95%) with one death, but if the intervention had 
affected mortality, then  would nevertheless estimate the causal effect on prevalence in 
the randomization cohort, measured in survivors.
 Cross-sectional studies
The assumptions that assure unbiasedness of estimator 2 are less straightforward in a cross-
sectional survey. We assume that survey participants are randomly selected from a well-
defined population of living people P1 at age a1 (no surrogates for the deceased). The 
presence (or absence) of disease at age a1 (Di,a1) and prior exposure at age a0 < a1 are 
accurately assessed.
Perhaps the main challenge is defining the target population needed to clearly define causal 
effects and for which a survey of population P1 is expected to yield valid estimates of causal 
prevalence differences. Because effects require time to occur, the target must have been 
enumerable at age a0 before measuring the outcome. We can clearly specify the target if 
population P1 consists of all survivors from a larger population P0 that was alive at the time 
of potential exposure, age a0. Population P0 should be definable by observable, 
contemporaneous factors. If we can specify P0, then measurement of disease prevalence in 
the survey provides just the information needed to estimate cPD and had a cohort study of P0 
been done. In particular, summation over i ∈ P0 appearing in estimator 2 can be replaced by 
summation over i ∈ P1 because summands Di,a1 and Si,a1 are 0 for individuals who die 
between age a0 and a1. If the survey involves a 100% sample, prevalences in the sample 
coincide with those from a cohort study of P0, and if less than 100%, prevalences are valid 
estimators of them because we assume exposure-specific prevalences in survey participants 
represent those in P1 (Appendix 1).
The other assumptions needed for unbiased estimation coincide with those for experiments 
and cohort studies. Specifically, we need exchangeability for target population P0 (Table 1; 
Di,a1 (e)∐Ei and Si,a1 (e)∐Ei for i ∈ P0 and SUTVA). These assumptions mean that 
comparison of disease status among exposed and unexposed survivors informs what would 
have happened if exposure had been randomized in population P0 at age a0 and the cohort 
followed to age a1.
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Some examples may help illustrate conceptualization of population P0 (Table 2). Suppose 
survey respondents, perhaps like respondents to the National Health and Nutrition 
Examination Survey or Behavioral Risk Factor Surveillance System, are representative of all 
(noninstitutionalized) U.S. residents, say at age a1, and that we focus on exposure at age a0. 
We exclude recent immigrants from P1 because they were not in the resident population at 
younger ages. Population P0 is then the population of residents at the younger age a0, a1 − a0 
years earlier. P1 should be (or represent) all in P0 who survive to a1. Emigration from P0 is 
permissible if independent of disease, survival, and exposure.
Figure 1 summarizes causal relationships that, if correct, assure the needed exchangeability 
assumptions for target population P0 and representativeness of the surveyed population (P1) 
using a directed acyclic graph (DAG). Rules for constructing and interpreting DAGs are 
reviewed in detail elsewhere [24–26]. The DAG shows that exposure E is (being assumed) 
independent of other causes of disease , and of other causes (U0) of disease and survival 
(S1). Membership in P1 depends on survival, not emigrating and other factors, but not 
directly on E. Participation depends on P1, other factors U1, but not directly on E. Under 
these causal patterns relationships, we expect exchangeability for target population P0 and 
representativeness survey population P1. Figure 2 illustrates situations wherein additional 
causal effects are present (dotted line) with both S1 and D1 affecting membership in P1. We 
now expect bias as survey population P1 may not represent all survivors from target 
population P0.
If the exposure-specific prevalences in survey participants do “not” represent those in P1 
(i.e., all P0-survivors), estimator [2] is likely biased. In this case, however, prevalent disease 
should be associated with survey participation, or with emigration or loss from the surviving 
population suggesting a common cause (e.g., C0 in Fig. 3). If we can control for all such 
common causes, prevalent disease should then be independent of participation, emigration, 
and loss (assuming no conditioning on a collider), exposure-specific prevalences in 
participants should consistently estimate those in survivors, and the conditional estimator 
should be consistent for the effect in [1].
 Example 2
Example 2 illustrates the use of prevalence contrasts for estimating effects in a survey 
(cross-sectional study). Our goal is to estimate the effect of starting smoking at age 18 years 
versus never starting or starting later on the prevalence of poor or fair health 20 years later at 
age 38 years. Self-rated health status is of interest partly because it consistently and strongly 
predicts subsequent mortality, even after control for multiple other health-status indicators 
[27]. To estimate this effect, we use data from the National Health and Nutrition 
Examination Survey for the years 2007–2010. To increase sample size, we include 
respondents 35–39 years old when surveyed (instead of just 38 years). The exposed group is 
smokers who started regular smoking between ages 18 and 21 years, using a wider age 
interval to increase sample size, and the unexposed are all who never started or started after 
age 21 years. The outcome is self-reported poor or fair health at interview (age, 35–39 
years). After adjusting for gender and race, the prevalence odds ratio was 1.7, indicating a 
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70% estimated higher prevalence odds of poorer health among those who started regular 
smoking at ages 18–21 years, compared with never or later starting smokers.
The baseline population P0 consisted of U.S. residents who were 18–21 years old about 20 
years before interview. If the exposed and unexposed were exchangeable conditional on 
controlled covariates, and participants were representative of all U.S. residents aged 38 ± 2 
years during this time period—the prevalence odds ratio should consistently estimate the 
effect of taking up regular smoking at about age 18 years on having self-reported poor health 
20 years later. Some U.S. residents died between ages 18 and 38 years possibly because of 
smoking. Because our interest is in the effect of smoking on prevalence, these deaths do not 
represent bias because of competing risks but rather are part of the defined effect of smoking 
[6] on subsequent disease prevalence among survivors.
 Discussion
When epidemiologists consider disease causation they almost invariably consider it in terms 
of disease onset (i.e., incidence). Rothman et al. developed causal concepts as follows ([5], 
p.6): “To begin, we need to define cause. One definition is the cause of a specific disease 
occurrence is an antecedent event, condition, or characteristic that was necessary for the 
occurrence of the disease at the moment it occurred, given that other conditions are fixed.” 
Although their interest in that definition is on disease onset, for effects on disease 
prevalence, we can similarly consider an antecedent event, condition, or characteristic that 
was necessary for an individual having disease at a particular point in time, given that other 
conditions are fixed. Effects on survival, disease onset, or disease duration in this context are 
part of the causal pathway.
A cohort study is often viewed as a natural design to estimate disease incidence, and a cross-
sectional study as a natural design to estimate prevalence as prevalence is a measure 
reflecting a moment in time. However, to study causal effects, the time sequence must be 
considered. So, to study causal effects on prevalence, a cohort study would be a natural 
design. Our assumptions provide conditions wherein observations from a cross-sectional 
study provide information that adequately approximates information from a cohort study for 
estimating effects on prevalence.
We have defined causal contrasts that compare the prevalence among survivors from the 
target population had all in the target been exposed at baseline with that prevalence had they 
been unexposed. The definition requires specification of the target population, exposure, 
ages, and other factors [2,6,28]. The assumptions needed for valid estimation are strong and 
require critical review to assess their validity. Each of these issues merits separate 
discussion.
A key assumption is that the baseline, target population be clearly defined and potentially 
enumerable. Although explicitly defined in experiments and cohort studies, in cross-
sectional studies, this baseline population may require conceptualization as an earlier 
“parent” population defined so that the population surveyed would consist of all (represent) 
survivors from the parent population. Identification of a parent population with the needed 
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characteristics creates a situation wherein observations from a cross-sectional study can 
reproduce those that would have been obtained if a cohort study of that population had been 
done. Many surveys will not permit clear delineation of the parent population; if not, 
associated causal-effect definitions may be unsatisfactory. Other assumptions for validity of 
the observed PD as an estimator of the causal PD in cross-sectional studies are equally 
important. In particular, exchangeability must be evaluated and, as in cohort studies, can be 
suspect. It is not expected to hold if confounding is present, perhaps due to causes of disease 
that are also associated with exposure. If the target is not disease free at baseline, 
exchangeability can also be suspect if the prevalence at baseline differs between the exposed 
and unexposed subgroups. In cross-sectional studies involving prevalence contrasts, 
exchangeability can be threatened by factors that affect either disease duration or risk and 
are associated with exposure. As with other observational studies, some assumptions are 
unverifiable, and sensitivity analyses may be useful.
The ages at exposure and at disease measurement must be clearly specified. These ages are 
critical for several reasons. First, age is a potential confounder, for example, if it affected 
prevalence and was associated with exposure. Second, age at exposure could be an effect 
measure modifier. Third, the age and time intervals between exposure (or nonexposure) and 
outcome measurement can also affect prevalence.
Ideally, exposure would have occurred, if at all, at age a0, the age of the target population at 
baseline, analogous to recommendations that follow-up in cohort studies begins at or before 
exposure [29–31]. To illustrate how we might define exposure and the target in practice, 
suppose our goal is to estimate the effect of hormone replacement therapy (HRT) on 
cardiovascular disease (CVD) prevalence. A population-based survey of 60 year olds is 
available that included questions about age at starting HRT. We could define “exposure” as 
having started HRT by a specific age, say 50 years (10 years before the survey) and 
“nonexposure” as not having started by that age (including never starting). P0 should consist 
of people who were 50 years old 10 years before the survey and should be defined so that P1 
consists of all survivors from P0. P0 may be easier to define if the survey is population-based 
(e.g., all 60-year-old, U.S. residents in 2010 excluding recent immigrants), so that it might 
be defined as the corresponding population, 10 years earlier (e.g., all 50-year-old, U.S. 
residents in 2000). See Appendix 2 for additional discussion. If the timing and ages are not 
specified, then the effect may not be clearly defined, and confusion can ensue. Importantly, 
similar issues can arise in cohort studies. A possible example concerns side effects of HRT, 
thought by many to be protective for CVD. After randomized trials showed HRT to increase 
rather than decrease CVD risk, reanalyses of one observational study suggested that better 
control for time since initiation and confounding could lead to better agreement with the 
randomized trial. Thus, clear specification of age at, and time since, exposure are important 
in cohort as well as cross-sectional studies [29,31] with exposure, if it occurs, being at or 
around the start of follow-up. Here, we restrict to specific ages for simplicity, but a stratified 
approach with calculation of summary measures or model-based estimation would directly 
extend our results.
A comparison of prevalences may seem wanting as a causal measure because prevalence is 
affected by disease incidence and duration (see Appendix 2) [23]. A harmful exposure could 
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increase the prevalence by increasing the rate of disease onset or decrease the prevalence by 
increasing the case fatality rate. Because the causal prevalence difference is a summary 
effect, use of additional contrasts such as differences in risk or duration can be helpful, 
sometimes vital. Nevertheless, prevalence itself is a widely reported and readily available 
epidemiologic measure for assessing disabilities, disease burden, and frequency, particularly 
for chronic, incurable diseases with long duration and unclear timing of onset [23]. Causal 
inference from prevalence has usually been considered as a proxy for incidence. Our 
purpose here and main novel result is to provide conditions for validly estimating causal 
effects in cross-sectional studies. However, we also discuss interpretation and related 
conceptual issues as the use of prevalence contrasts for defining and estimating causal 
effects is uncommon and involves relatively new considerations.
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 Appendix 1
 Experiments
We argue that the estimator (expression 2) is unbiased under our assumptions for 
experiments. By completeness of follow-up, Nj,a1 = ∑i∈P0:Ei=jSi,a1 for j = 0 or 1, where 
Si,a1=1 if subject i is alive at age a1 and 0 otherwise. By counterfactual model consistency 
for both Di,a1(e) and Si,a1 (e), ∑i∈P0:Ei=jDi,a1/∑i∈P0:Ei=jSi,a1 = ∑i∈P0:Ei=jDi,a1 (j)/
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∑i∈P0:Ei=jSi,a1 (j). By exchangeability, E[∑i∈P0:Ei=jDi,a1 (j)]/E[∑i∈P0:Ei=jSi,a1 (j)] = ∑i∈P0Di,a1 
(j)/∑i∈P0Si,a1 (j). Slutsky’s theorem [32] now implies that expression [2] is unbiased 
(technically, consistent) for the causal effect (Equation 1).
 Cohort studies
To estimate the cPD in a cohort study, we select a cohort P0, some of whom were exposed at 
baseline (age a0), others not. The assumptions needed for unbiasedness of estimator 2 are the 
same as those for an experiment. However, exchangeability, which should hold in an 
experiment with good randomization, needs to be critically evaluated. In particular, we must 
verify that collider bias [4,5,33,34], if any, induced by cohort selection at baseline is 
negligible. We follow the cohort to age a1 and assess disease presence.
Our claim, that estimator [2] is unbiased given our assumptions, follows from the preceding 
arguments as the design and assumptions closely parallel those for an experiment. The key 
difference for cohort studies is that the assumption of exchangeability is not expected to hold 
by design, at least absent restriction, stratification or adjustment, and must be evaluated with 
particular care using all available information.
 Cross-sectional studies
Finally, we argue that estimator 2 is consistent under our assumptions for cross-sectional 
studies. By assumption, the sample is representative of population P1, so 
, where the summation is over 
subjects in population P1. Also, by assumption, a larger, enumerable population P0 exists 
such that P1 consists of all surviving members of P0. Because Di,a and Si,a are both 0 for the 
deceased, we have in expectation, 
.
This last expression is the same as estimator 2 for the target cohort P0 if it was the baseline 
population in a cohort study followed from age a0 to age a1. But estimator 2 is unbiased by 
our assumptions and arguments mentioned previously for the cohort P0.
At times, an alternative estimator that accounts for baseline prevalence may be unbiased 
even if estimator 2 is biased.
(3)
For example, the prevalence at baseline may differ between exposed and unexposed because 
of factors associated with exposure but unassociated with changes in disease thereafter. 
Measurement error can affect the decision to further account or adjust for baseline disease 
status as discussed by Glymour et al. [35].
Flanders et al. Page 11
Ann Epidemiol. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
 Appendix 2
 Alternative approach to defining prevalence effects
Here we consider an approach to defining prevalence effects that provides more details, still 
rooted in the general causal-effect definition which contrasts parameters of the multivariate 
counterfactual-outcome distributions presented by Flanders and Klein [1]. The idea is to 
separate and incorporate the three components of prevalence: disease onset, disease duration, 
and survival. Di,a defined in the main text can be viewed as an infinite-dimensional vector, 
Di that traces the disease and survival status of individual i over each moment of the period 
of interest. The ath component of Di = Di,a encodes disease presence, as defined in the main 
text, for each age a ≥ 0. Similarly, the ath components of Di(e), Si(e) and Si are Di,a(e), Si,a(e) 
and Si,a respectively. Using Di(e), a matrix of counterfactual outcomes consisting of three 
vectors can be derived:
where ti,k(e) represents the time from baseline (time 0 or age a0) to the kth disease episode of 
subject i, and ni(e) is the total number of his/her episodes during the observation period, if Ei 
were set to e at baseline. If subject i has disease at baseline then ti, 1(e) is zero. ui,k(e) 
represents the duration of the kth episode of subject i, if Ei were e. If subject i has disease at 
baseline then ui, 1(e) is the duration of the first episode from baseline.  represents 
survival time from baseline. The superscript δ (in  and  is 1 if 
information is censored and 0 otherwise.
This formulation includes details about disease onset and duration for potentially multiple 
disease episodes over time. With it, causal effects of exposure on prevalence can be traced 
over time since baseline. Additionally, this information allows consideration of the causal 
effect of exposure on disease onset, survival, cumulative disease duration, average duration 
per episode, proportion of time with the disease or condition and the number of episodes.
 Comparison of causal prevalence differences (Equation 1) with causal conditional risk 
differences
One of the examples used by Flanders and Klein to illustrate their general, multivariate 
definition of causal effects was the causal conditional risk difference (cCRD) [1]. Here we 
compare the cCRD with the causal Prevalence Difference (cPD) given by Equation (1). The 
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cCRD for the risk of an outcome during a risk period for the target P0, conditional on 
survival to age a, can be defined for the target P0 by:
(1A)
where Ii,a(e) is 1 if the outcome of interest occurs between age a and before the end of the 
risk period and as 0 otherwise. This expression is like Expression 1 of the main text, but 
Ii,a(e) replaces Di,a(e) and is defined differently. The definition of cPD is similar, but 
involves presence of disease at age a (reflected in Di,a(e)), rather than occurrence of disease 
in the risk period starting at age a (reflected in Ii,a(e)).
 The causal prevalence difference estimator (expression 2) and potential collider bias
Since the denominator of Estimator 2 equals the number in the baseline population (target 
P0) who survive to age a1, one could, and a reviewer did, ask if the estimator in Equation 2 
might be affected by collider bias due to conditioning on survival to age a1. A theoretical 
justification that the estimator in Equation 2 is consistent is outlined in Appendix 1. Here, 
we provide alternative, less technical arguments. (Briefly, that justification uses the 
assumptions in the main text including exchangeability in the target P0 and SUTVA to show 
that (∑i∈P0:Ei=e Di,a/Np0,e, ∑i∈P0:Ei=eSi,a/Np0,e) is an unbiased estimator of the population-
average, multivariate effect of E on outcome vector (Di, Si), where Np0,e is the number in P0 
with E = e. Slutsky’s theorem then shows consistency for the ratio contrasts–the prevalence 
difference.) Collider bias for one target (e.g., P1) but not another (e.g. P0), is also discussed 
elsewhere [1].
First, we emphasize that the target population is selected at baseline (time 0), and the 
exposure is independent of risk factors for disease and survival in this population 
(exchangeability assumption, perhaps conditional on common causes). Thus, selection 
(collider bias) from selection of the target is not an issue, by assumption. Furthermore, the 
final estimator (equation 2) is merely an algebraic manipulation of the multivariate estimator 
(∑i∈P0:Ei=e Di,a/Np0,e, ∑i∈P0:Ei=eSi,a/Np0,e). But this multivariate estimator involves no 
exclusions, stratification, or control (except for stratification by exposure which is 
exchangeable), and so involves no collider bias.
Second, we note reassuringly that the cPD (equation 1) is directly estimable in a well-
conducted experiment (using estimator 2), in which exposure is randomized at baseline in 
the target P0. The causal prevalence difference addresses the question – “What is the 
population average effect of exposure on the target population, as measured by disease 
prevalences at age a1?” Of course other question can and typically should be asked, such as, 
“What is the population average effect of exposure on the target population, as measured by 
survival at age a1?” or “What is the population average effect of exposure on the target 
population, as measured by disease incidence through age a1?” Although other questions 
exist, by randomizing exposure at baseline, following the exposed and unexposed groups to 
age a1, and then accurately measuring disease presence and contrasting the prevalences, one 
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can consistently estimate the effect of exposure on prevalence (via estimator 2). Thus, the 
defined effect (expression 1) is directly observable using simple, well-defined procedures 
that end by using estimator 2 in a randomized experiment.
Third, we note that effects of exposure, if any, on death before age a1, are part of the defined 
effect on prevalence (Expression 1), and appropriately reflected in defining the effect and 
calculating the measure that estimates it. For example, one way in which exposure could 
cause a reduction in disease prevalence at age a1 would be to differentially reduce survival 
among those who had developed disease. Such a prevalence reduction would be an expected 
part of an effect on prevalence and correctly estimated, in a randomized experiment or other 
study under our assumptions. Through use of multivariate outcomes and effects, as described 
above, a more complete characterization of the exposure’s impacts can be obtained.
 Supplemental Example 1
Supplemental example 1 illustrates use of prevalence contrasts for estimating effects in a 
cohort study. To estimate effects of early-life factors on sedentary lifestyle in adolescents, 
Hallal et al. [2] conducted a cohort study of all children born in-hospital, during 1993 in 
Pelotas, Brazil. They found a sedentary-lifestyle prevalence of 53.5% among 10–12 year 
olds whose mother had low education, compared to 63.2% among those whose mother had 
high education. The prevalence difference (9.7%), if exchangeability and our other 
assumptions are adequately approximated, is interpretable as the effect of maternal 
education on prevalence of sedentary lifestyle in adolescents and illustrates use and 
estimation of prevalence contrasts in a cohort study.
 Additional considerations in defining exposures for potentially-ongoing exposures
To further illustrate issues that can arise in defining exposure contrasts and the target P0, 
consider the effects of starting alcohol use at a young age, say age 15, on prevalence of 
hepatic disease at age 35. We might define exposure as having started regular heavy alcohol 
use by age 15, and for comparison an “unexposed” group as those who had not started 
regular, heavy drinking by age 15. The resulting contrast, just as it would be in a cohort 
study, actually compares the effect of starting alcohol use early (age 15) versus later or 
never. The presence of people who later became a regular heavy drinker would, just as in a 
cohort study, reduce the expected effects of heavy drinking–compared to a completely 
unexposed population of, say, never drinkers. But, even in a cohort study–accounting for 
changes in exposure might require G-computation or related method [3] – if those changes 
reflect time-varying confounding. If a population-based survey of 35 year olds is available, 
P0 should be defined, if possible, as those who were 15 years old about 20 years before the 
survey, in a way that the survey population represents all survivors from P0.
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Fig. 1. 
The figure summarizes causal relationships using a DAG for the baseline population P0. If 
correct, estimator 2 should be unbiased (see text). D1 represents disease presence at age a1, 
 other causes of disease, U0 other causes of survival (S1), and disease (D1). P1 is the 
survey population; membership depends deterministically on survival, and not emigrating or 
other loss, but not directly on exposure E or D1. Participation depends on P1 and other 
factors U1. †Emigration, other factors affect being in population P1.
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Fig. 2. 
The figure illustrates a situation such as that in Figure 1, with an additional effect (dotted 
line) that could underlie bias in estimator 2. For example, bias is expected if S1 and D1 affect 
membership in P1 (see text). D1 represents disease presence at age a1,  other causes of 
disease, U0 other causes of survival (S1), and disease. P1 is the survey population; 
membership depends on survival, not emigrating, and D1. Participation depends on P1 and 
other factors U1. †Emigration, other factors affect being in population P1.
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Fig. 3. 
The figure illustrates a situation such as that in Figure 1, but with a common cause (C0) of 
prevalent disease D1 and emigration. Exposure-specific prevalences in the survey population 
(P1) would be expected to differ from those in all survivors, and bias is expected. 
represents other causes of disease, U0 other causes of survival (S1), and disease. P1 is the 
survey population; membership depends deterministically on survival, not emigrating or 
other loss, and D1. Participation depends on P1 and other factors U1. †Emigration, loss other 
factors affect being in population P1. ††C0 is common cause of prevalent disease and 
emigration, so prevalence in P1 expected to differ from that in all survivors.
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Table 1
Definitions and notation
Term Brief definition
[Di,a(e), Si,a(e)] counterfactual outcome vector Components are counterfactual outcomes Di,a(e), Si,a(e) defined next. [Di,a(e), Si,a(e)] = [1,1] if 
subject i is alive with
disease at age a; = [0,1] if subject i is alive without disease at age; = [0,0] if subject i is not 
alive at age a; all if
exposure had been set to e
Di,a(e)—counterfactual disease outcome First component of counterfactual-outcome vector [Di,a(e), Si,a(e)], defined previously
Si,a(e)—counterfactual survival, subject i second component of counterfactual-outcome vector [Di,a(e), Si,a(e)], defined previously
Di,a(1) − Di,a(0) Individual causal effect on disease presence at age a
cPD—causal prevalence difference Population-average effect of exposure at age a0 on disease prevalence at a, in defined target 
population (Equation 1),
Exchangeability—disease The counterfactual outcome with E set to e, is independent of actual exposure: Di,a(e)∐Ei; 
exchangeability can be
conditional on covariates C: Di,a(e)∐Ei|C
Exchangeability—survival The counterfactual outcome with E set to e, is independent of actual exposure: Si,,a(e)∐Ei; 
exchangeability can be
conditional on covariates C: Si,a(e)∐Ei|C
Consistency The observed outcome equals the counterfactual outcome if exposure were set to the actual 
exposure: Di,a(e)=Di,a
if Ei=e
Stable unit treatment value assumption The outcome of individual i is independent of the exposure status of all other individuals: 
Di,a(e)∐Ej for i ≠ j
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Table 2
Examples of surveys for which the “parent” population P0 may be specifiable*
Survey Population P1 Parent Population P0
Population-based national survey
  (e.g. NHANES 3)
U.S. residents, noninstitutionalized, age a1—excluding 
immigrants
between age a0 and a1
U.S. residents, noninstitutionalized,
age a0, (a0< a1)
Population-based statewide 
telephone
  ssurveys (e.g., BRFSS)
State residents, noninstitutionalized, age a1—excluding 
immigrants
between age a0 and a1
State residents, noninstitutionalized,
age a0, (a0< a1)
Population-based national telephone
  survey (e.g., NHIS)
U.S. residents, noninstitutionalized, age a1—excluding 
immigrants
between age a0 and a1
U.S. residents, noninstitutionalized,
age a0, (a0< a1)
BRFSS = Behavioral Risk Factor Surveillance System; NHANES = National Health and Nutrition Examination Survey; National Health Interview 
Survey (NHIS).
*P0: as in the main text, P1 is the population (age a1) sampled for the survey, and P0 is the parent population (age a0) defined so that P1 consists 
of all surviving members of P0. To assure temporal precedence, a0 is less than a1.
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